Opening the Vessel Is Not Enough – Is Cerebrolysin^® the Answer for Improved Long-Term Outcomes After Recanalization Therapy?

The ongoing CERECAP (CErebrolysin RECanalization And -Perfusion) pilot trial series investigates whether adding a cerbroprotective agent, like Cerebrolysin^®, to recanalization therapy can improve long-term outcomes in stroke patients, and whether certain patient groups benefit more than others. The panel, consisting of leading stroke experts all over the world, shared their clinical experiences using Cerebrolysin^® as an adjunct to standard treatment.

Please find all details in the report below.

The full recording of the event can you find here.